Global T-Cell Therapy Market Size, Trends & Growth Opportunity, By Modality (Research, and Commercialized), By Therapy Type (CAR T-cell Therapy, T Cell Receptor (TCR)-based, and Tumor Infiltrating Lymphocytes (TIL)-based), By Indication, By End User, By Region and Forecast from 2022-2027.
Global T-Cell Therapy Market
Global T-Cell Therapy Market was valued at USD 4.2 billion in 2021 which expected to reach USD 24.6 billion by 2027 at a CAGR 28.75%.
T-cells are a type of white blood cell that aid in the body's defence against infection and may even aid in the battle against cancer. It is also a component of the immune system. As a cutting-edge immunotherapy that aids in the treatment of various tumours, T-cell therapy is characterised. These modified cells are multiplied and then injected into the body to identify and eradicate cancer cells that have certain antigens on their surface.
Market Drivers
The global T-cell therapy market is anticipated to develop over the course of the forecast period due to the rise in cancer incidence and the rising number of patients who do not respond to alternative treatments. Additionally, it is projected that the rise in the number of adults and children contracting cancer would increase the need for an efficient and dependable therapeutic treatment technique to enhance the quality of patients' lives. For instance, according to data from Cancer Research UK, 14.1 million individuals worldwide were diagnosed with cancer in 2012.
Another important element propelling the expansion of the worldwide T-cell therapy market is the creation of fresh and efficient treatment choices to treat disease symptoms. For example, the U.S. Food and Drug Administration approved two CAR-T cell therapies in 2017 under the names Kymriah and Yescarta for the treatment of adult and pediatric lymphoblastic leukemia and advanced lymphoma, respectively. Over the course of the projection period, this is anticipated to fuel market expansion. The expansion of the worldwide T-cell therapy market is also being supported by the rise in government programmed for enhancing health systems and encouraging research for cell treatment in cancer.
Market Restraints
Cytokine release syndrome (CRS), as well as other neurological issues like seizures, coma, hallucinations, and delirium, may be brought on by T-cell treatment side effects. These are significant restraints that are anticipated to have a negative impact on the market for T-cell treatment globally throughout the projected period.
Market Segmentation
The Global T-Cell Therapy Market is segmented into Modality such as Research, and Commercialized. The research segment dominates the market with considerable market share in 2020, due to the high number of products in the clinical development phase. On the basis of therapy type, market is segmented into CAR T-cell Therapy, T Cell Receptor (TCR)-based, and Tumor Infiltrating Lymphocytes (TIL)-based. CAR T-cell therapy is fastest growing segment in the market. This is due to the exponential rise in the number of clinical trials for CAR-T therapies. On the basis of indication market is segmented into Hematologic Malignancies, Solid Tumors, and Others. Also, the market is segmented into end users such as Hospitals, Clinics & Ambulatory Centers, Cancer Research Institutes, and Others. 
Impact of COVID-19
The COVID-19 pandemic has sparked a surge in funding for studies into how T-cell treatments can be used to treat viral infections. For instance, research released in December 2020 showed the therapy's potential to help high-risk COVID-19 patients. It is anticipated that this will lead to a rise in the use of T-cell therapies for viral infections.
Regional Analysis
The Global T-Cell Therapy Market is segmented into five regions such as North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.
The North American area dominates the global T-cell therapy industry in terms of revenue share. owing to the region's quick discovery and introduction of novel cancer medicines. For instance, according to data from the Centers for Disease Control and Prevention (CDC), around 171,000 people were diagnosed with blood cancer in the United States in 2016. Due to growing investment & significant research for the development of cancer therapeutics in the region, Europe is anticipated to be the second most important market in terms of revenue.
Key Players
Key Players operating in the global T-cell therapy market is include Novartis AG, Amgen, Celgene Corporation, Pfizer Inc., Fate Therapeutics, Bluebird Bio Inc., TCR2 Therapeutics Inc, Sorrento Therapeutics, Gilead Sciences Inc., Merck KGaA, etc.The competitive environment of the T-cell therapy market is anticipated to be impacted by the increasing number of businesses engaged in the development of CAR-T treatments. The market for T-cell treatment is now controlled by Novartis AG thanks to new product development and developments.
Market Taxonomy
By Modality
•        Research
•        Commercialized
By Therapy Type
•        CAR T-cell Therapy
•        T Cell Receptor (TCR)-based
•        Tumor Infiltrating Lymphocytes (TIL)-based
By Indication
•        Hematologic Malignancies
•        Solid Tumors
•        Others
By End User
•        Hospitals
•        Clinics & Ambulatory Centers
•        Cancer Research Institutes
•        Others
By Region
•        North America
•        Latin America
•        Europe
•        Asia Pacific
•        Middle East & Africa

Global T-Cell Therapy Market TOC:
1 Introduction
1.1 Objective of the Study
1.2 Market definition
1.3 Market Scope
2 Research Methodology
2.1 Data Mining
2.2 Validation
2.3 Primary Interviews
2.4 List of Data Sources
3 Executive Summary
4 Global T-Cell Therapy Market Outlook
4.1 Overview
4.2 Market Dynamics
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.3 Porters Five Force Model
4.4 Value Chain Analysis
5 Global T-Cell Therapy Market, By Modality
5.1 Y-o-Y Growth Comparison, By Modality 
5.2 Global T-Cell Therapy Market Share Analysis, By Modality 
5.3 Global T-Cell Therapy Market Size and Forecast, By Modality
5.3.1 Research
5.3.2 Commercialized
6 Global T-Cell Therapy Market, By Therapy Type
6.1 Y-o-Y Growth Comparison, By Therapy Type
6.2 Global T-Cell Therapy Market Share Analysis, By Therapy Type
6.3 Global T-Cell Therapy Market Size and Forecast, By Therapy Type
6.3.1 CAR T-cell Therapy
6.3.2 T Cell Receptor (TCR)-based
6.3.3. Tumor Infiltrating Lymphocytes (TIL)-based
7 Global T-Cell Therapy Market, By Indication
7.1 Y-o-Y Growth Comparison, By Indication
7.2 Global T-Cell Therapy Market Share Analysis, By Indication
7.3 Global T-Cell Therapy Market Size and Forecast, By Indication
7.3.1 Hematologic Malignancies
7.3.2 Solid Tumors
7.3.3 Others
8 Global T-Cell Therapy Market, By End User
8.1 Y-o-Y Growth Comparison, By End User
8.2 Global T-Cell Therapy Market Share Analysis, By End User
8.3 Global T-Cell Therapy Market Size and Forecast, By End User
8.3.1 Hospitals
8.3.2 Clinics & Ambulatory Centers
8.3.3 Cancer Research Institutes
8.3.4 Others
9Global T-Cell Therapy Market, By Region
9.1 Global T-Cell Therapy Market Share Analysis, By Region
9.2 Global T-Cell Therapy Market Share Analysis, By Region
9.3 Global T-Cell Therapy Market Size and Forecast, By Region
10 North America T-Cell Therapy Analysis and Forecast (2022-2027)
10.1 Introduction
10.2 North America T-Cell Therapy Product Market Share Analysis, By Modality
10.3 North America T-Cell Therapy Product Market Size and Forecast, By Therapy Type
10.4 North America T-Cell Therapy Product Market Size and Forecast, By Indication
10.5 North America T-Cell Therapy Product Market Size and Forecast, By End User
10.6 North America T-Cell Therapy Product Market Size and Forecast, By Country
10.6.1 U.S.
10.6.2 Canada
10.6.3 Mexico
11Europe T-Cell Therapy Market Analysis and Forecast (2022-2027)
11.1 Introduction
11.2 Europe T-Cell Therapy Product Market Share Analysis, By Modality 
11.3 Europe T-Cell Therapy Product Market Size and Forecast, By Therapy Type 
11.4 Europe T-Cell Therapy Product Market Size and Forecast, By Indication
11.5 Europe T-Cell Therapy Product Market Size and Forecast, By End User
11.6 Europe T-Cell Therapy Product Market Size and Forecast, By Country
11.6.1 Germany
11.6.2 France
11.6.3 UK
11.64. Rest of Europe
12Asia Pacific T-Cell Therapy Market Analysis and Forecast (2022-2027)
12.1 Introduction
12.2 Asia Pacific T-Cell Therapy Product Market Share Analysis, By Modality 
12.3 Asia Pacific T-Cell Therapy Product Market Size and Forecast, By Therapy Type  
12.4 Asia Pacific T-Cell Therapy Product Market Size and Forecast, By Indication
12.5 Asia Pacific T-Cell Therapy Product Market Size and Forecast, By End User
12.6 Asia Pacific T-Cell Therapy Product Market Size and Forecast, By Country
12.6.1 China
12.6.2 Japan
12.6.3 India
12.6.4. Rest of Asia Pacific
13Latin America T-Cell Therapy Market Analysis and Forecast (2022-2027)
13.1 Introduction
13.2 Latin America T-Cell Therapy Product Market Share Analysis, By Modality 
13.3 Latin America T-Cell Therapy Product Market Size and Forecast, By Therapy Type 
13.4 Latin America T-Cell Therapy Product Market Size and Forecast, By Indication
13.5 Latin America T-Cell Therapy Product Market Size and Forecast, By End User
13.6 Latin America T-Cell Therapy Product Market Size and Forecast, By Country
14Middle East T-Cell Therapy Market Analysis and Forecast (2022-2027)
14.1 Introduction
14.2 Middle East T-Cell Therapy Product Market Share Analysis, By Modality 
14.3 Middle East T-Cell Therapy Product Market Size and Forecast, By Therapy Type 
14.4 Middle East T-Cell Therapy Product Market Size and Forecast, By Indication
14.5 Middle East T-Cell Therapy Product Market Size and Forecast, By End User
14.6 Middle East T-Cell Therapy Product Market Size and Forecast, By Country
15Competitive Analysis
15.1 Competition Dashboard
15.2 Market share Analysis of Top Vendors
15.3 Key Development Strategies
16Company Profiles
16.1 Novartis AG
16.1.1 Overview
16.1.2 Offerings
16.1.3 Key Financials
16.1.4 Business Segment & Geographic Overview
16.1.5 Key Market Developments
16.1.6 Key Strategies
16.2 Amgen
16.2.1 Overview
16.2.2 Offerings
16.2.3 Key Financials
16.2.4 Business Segment & Geographic Overview
16.2.5 Key Market Developments
16.2.6 Key Strategies
16.3 Celgene Corporation
16.3.1 Overview
16.3.2 Offerings
16.3.3 Key Financials
16.3.4 Business Segment & Geographic Overview
16.3.5 Key Market Developments
16.3.6 Key Strategies
16.4 Pfizer Inc
16.4.1 Overview
16.4.2 Offerings
16.4.3 Key Financials
16.4.4 Business Segment & Geographic Overview
16.4.5 Key Market Developments
16.4.6 Key Strategies
16.5 Fate Therapeutics
16.5.1 Overview
16.5.2 Offerings
16.5.3 Key Financials
16.5.4 Business Segment & Geographic Overview
16.5.5 Key Market Developments
16.5.6 Key Strategies
16.6 Bluebird Bio Inc
16.6.1 Overview
16.6.2 Offerings
16.6.3 Key Financials
16.6.4 Business Segment & Geographic Overview
16.6.5 Key Market Developments
16.6.6 Key Strategies
16.7 TCR2 Therapeutics Inc
16.7.1 Overview
16.7.2 Offerings
16.7.3 Key Financials
16.7.4 Business Segment & Geographic Overview
16.7.5 Key Market Developments
16.7.6 Key Strategies        
16.8 Sorrento Therapeutics
16.8.1 Overview
16.8.2 Offerings
16.8.3 Key Financials
16.8.4 Business Segment & Geographic Overview
16.8.5 Key Market Developments
16.8.6 Key Strategies        
16.9 Gilead Sciences Inc
16.9.1 Overview
16.9.2 Offerings
16.9.3 Key Financials
16.9.4 Business Segment & Geographic Overview
16.9.5 Key Market Developments
16.9.6 Key Strategies        
16.10 Merck KGaA
16.10.1 Overview
16.10.2 Offerings
16.10.3 Key Financials
16.10.4 Business Segment & Geographic Overview
16.10.5 Key Market Developments
16.10.6 Key Strategies